Sanofi 3rd-qtr 2011 net profit falls 3%, hit by generic competition
Sanofi’s (Euronext: SAN) group sales for the third quarter of 2011 came in at 8.75 billion euros ($12.08 billion), up 5% on a reported basis (+10.1% at constant exchange rates), slightly below consensus estimates of 8.9 billion euros and hit by generic competition on three of its drugs.
However, the French drug major said that, excluding Genzyme, the $21.1 plus CVR acquisition of which was completed this spring, revenues were stable despite 471 million euros of sales lost due to generic competition compared with third-quarter 2010. Business net income (non-GAPP) was down 3% (+4.1% at CER) to 2.4 billion euros with business earnings per share falling 5.3% (+1.6% at CER) to 1.79 euros. This beat the 2.33 billion-euro average estimate of 16 analysts compiled by Bloomberg.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze